新型冠状病毒肺炎(COVID-19)抗病毒药物治疗进展  

Progress in coronavirus disease 2019 treatment with antiviral drugs

作　　者：苏广胜(综述) 谷秀(审校)[2] Su Guangsheng;Gu Xiu(Department of Cardiovascular Medicine,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院心血管内科,沈阳110004 [2]中国医科大学附属盛京医院呼吸与危重症医学科,沈阳110004

出　　处：《疑难病杂志》2020年第6期548-551,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：新型冠状病毒感染由于其传染能力较强,被国家卫生健康委员会归为乙类传染病,按甲类传染病管理,到目前为止无特效药物可以治疗。国家卫健委发布的《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》,提及了几种以往用于治疗其他病毒感染的抗病毒药物,尝试应用于治疗新型冠状病毒肺炎,现通过检索大量文献,总结既往干扰素α、阿比多尔、洛匹那韦/利托那韦、磷酸氯喹、利巴韦林治疗SARS-CoV、MERS-CoV、其他病毒感染的有效性和发生新型冠状病毒肺炎以来进行的试验研究,以期为上述药物治疗新型冠状病毒肺炎提供理论依据。The coronavirus disease 2019 is a class B infectious disease due to its strong infectious capacity.It is managed by class A infectious diseases and so far,no specific drugs are available.The coronavirus disease 2019 diagnosis and treatment plan(trial version sixth)released by the national health and Health Committee,mentioned several antiviral drugs formerly used to treat other viral infections,and tried to apply for the treatment of coronavirus disease 2019.A large number of literatures have been searched to summarize the effectiveness and efficacy of previous interferonα,abidor,lopinavir/ritonavir,chloroquine phosphate,ribavirin in the treatment of SARS CoV,MERS CoV,and other viral infections.Experimental studies conducted since the occurrence of new coronavirus pneumonia,with a view to provide a theoretical basis for the treatment of coronavirus disease 2019 with the above drugs.

关 键 词：新型冠状病毒 新型冠状病毒肺炎 抗病毒药物 进展 

分 类 号：S85[农业科学—兽医学]